Expanding Sterile Fill-Finish for the Next Era of Biologics

Jason Spacek, Chief Commercial Officer, discusses Afton Scientific, shares his perspective on the industry’s exciting transition away from blockbuster drugs and toward specialized biologics and precision treatments for smaller patient populations, and plans for the company’s new large-scale facility slated to begin operations in 2028.